{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:07:42Z","timestamp":1790834862034,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,8,7]],"date-time":"2004-08-07T00:00:00Z","timestamp":1091836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Retinopathy of Prematurity (ROP) is a common retinal neovascular disorder of premature infants. It is of variable severity, usually heals with mild or no sequelae, but may progress to blindness from retinal detachments or severe retinal scar formation. This is a preliminary report of the effectiveness and safety of a new and original use of topical ketorolac in preterm newborn to prevent the progression of ROP to the more severe forms of this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2001 to December 2002, all fifty nine preterm newborns with birthweight less than 1250 grams or gestational age less than 30 weeks of gestational age admitted to neonatal intensive care were eligible for treatment with topical ketorolac (0.25 milligrams every 8 hours in each eye). The historical comparison group included all 53 preterm newborns, with the same inclusion criteria, admitted between January 1999 and December 2000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Groups were comparable in terms of weight distribution, Apgar score at 5 minutes, incidence of sepsis, intraventricular hemorrhage and necrotizing enterocolitis. The duration of oxygen therapy was significantly longer in the control group. In the ketorolac group, among 43 children that were alive at discharge, one (2.3%) developed threshold ROP and cryotherapy was necessary. In the comparison group 35 children survived, and six child (17%) needed cryotherapy (Relative Risk 0.14, 95%CI 0.00 to 0.80, p = 0.041). Adjusting by duration of oxygen therapy did not significantly change these results. Adverse effects attributable to ketorolac were not detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This preliminary report suggests that ketorolac in the form of an ophthalmic solution can reduce the risk of developing severe ROP in very preterm newborns, without producing significant adverse side effects. These results, although promising, should be interpreted with caution because of the weakness of the study design. This is an inexpensive and simple intervention that might ameliorate the progression of a disease with devastating consequences for children and their families. We believe that next logical step would be to assess the effectiveness of this intervention in a randomized controlled trial of adequate sample size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2431-4-15","type":"journal-article","created":{"date-parts":[[2004,8,10]],"date-time":"2004-08-10T02:35:20Z","timestamp":1092105320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: a preliminary study"],"prefix":"10.1186","volume":"4","author":[{"given":"Medardo","family":"Avila-Vazquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roque","family":"Maffrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Vaca","family":"de Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Cafferata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,8,7]]},"reference":[{"issue":"11","key":"42_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","volume":"98","author":"EA Palmer","year":"1991","unstructured":"Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B: Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991, 98 (11): 1628-1640.","journal-title":"Ophthalmology"},{"issue":"1 Pt 1","key":"42_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1542\/peds.102.1.31","volume":"102","author":"K Wright","year":"1998","unstructured":"Wright K, Anderson ME, Walker E, Lorch V: Should fewer premature infants be screened for retinopathy of prematurity in the managed care era?. Pediatrics. 1998, 102 (1 Pt 1): 31-4. 10.1542\/peds.102.1.31.","journal-title":"Pediatrics"},{"issue":"3","key":"42_CR3","first-page":"227","volume":"79","author":"Cl Gilbert","year":"2001","unstructured":"Gilbert Cl: Childhood Blindness in the context of VISION 2020 \u2013 the right to sight. Bull Word Health Organ. 2001, 79 (3): 227-32.","journal-title":"Bull Word Health Organ"},{"key":"42_CR4","volume-title":"International Center for Eye Health, London University, UK","author":"MT Arrazola Berrizbeitia","year":"1997","unstructured":"Arrazola Berrizbeitia MT: Retinopat\u00eda del Prematuro en Argentina. International Center for Eye Health, London University, UK. 1997"},{"key":"42_CR5","doi-asserted-by":"crossref","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Pediatrics. 1988, 81 (5): 697-706.","DOI":"10.1542\/peds.81.5.697"},{"issue":"4","key":"42_CR6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0031-3955(16)38581-9","volume":"40","author":"DL Phelps","year":"1993","unstructured":"Phelps DL: Retinopathy of prematurity. Pediatr Clin North Am. 1993, 40 (4): 705-14.","journal-title":"Pediatr Clin North Am"},{"key":"42_CR7","first-page":"2249","volume-title":"In: Fetal and Neonatal Physiology","author":"GE Quinn","year":"1998","unstructured":"Quinn GE: Retinal Development and the Pathophysiology of Retinopathy of Prematurity. In: Fetal and Neonatal Physiology. Edited by: Polin and Fox. 1998, WB Saunders Company, 200: 2249-55. Second","edition":"Second"},{"issue":"13","key":"42_CR8","first-page":"4236","volume":"35","author":"V Dobson","year":"1994","unstructured":"Dobson V, Quinn GE, Summers CG, Saunders RA, Phelps DL, Tung B, Palmer EA: Effect of acute-phase retinopathy of prematurity on grating acuity development in the very low birth weight infant. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Invest Ophthalmol Vis Sci. 1994, 35 (13): 4236-44.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"42_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0161-6420(01)00540-1","volume":"108","author":"WV Good","year":"2001","unstructured":"Good WV, Hardy RJ: The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). Ophthalmology. 2001, 108 (6): 1013-4. 10.1016\/S0161-6420(01)00540-1.","journal-title":"Ophthalmology"},{"issue":"6","key":"42_CR10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0022-3476(97)70031-3","volume":"131","author":"TN Raju","year":"1997","unstructured":"Raju TN, Langenberg P, Bhutani V, Quinn G: Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr. 1997, 131 (6): 844-50.","journal-title":"J Pediatr"},{"key":"42_CR11","doi-asserted-by":"crossref","unstructured":"Phelps DL, Lakatos L, Watts JL: D-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2001, CD001073-1","DOI":"10.1002\/14651858.CD001073"},{"issue":"1","key":"42_CR12","doi-asserted-by":"publisher","first-page":"F27","DOI":"10.1136\/fn.73.1.F27","volume":"73","author":"GA Russell","year":"1995","unstructured":"Russell GA, Cooke RW: Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed. 1995, 73 (1): F27-31.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"42_CR13","doi-asserted-by":"crossref","unstructured":"Phelps DL, Watts JL: Early light reduction for preventing retinopathy of prematurity in very low birth weight infants. Cochrane Database Syst Rev. 2001, CD000122-1","DOI":"10.1002\/14651858.CD000122"},{"key":"42_CR14","doi-asserted-by":"crossref","unstructured":"Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000, 105 (2): 295-310. 10.1542\/peds.105.2.295.","DOI":"10.1542\/peds.105.2.295"},{"key":"42_CR15","doi-asserted-by":"crossref","unstructured":"Hardy P, Dumont I, Bhattacharya M, Hou X, Lachapelle P, Varma DR, Chemtob S: Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res. 47 (3): 489-509. 10.1016\/S0008-6363(00)00084-5. 2000 Aug 18","DOI":"10.1016\/S0008-6363(00)00084-5"},{"issue":"9","key":"42_CR16","first-page":"1647","volume":"38","author":"L Aiello","year":"1997","unstructured":"Aiello L: Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci. 1997, 38 (9): 1647-52.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"42_CR17","doi-asserted-by":"crossref","unstructured":"Ishida S, Usui T, Yamashiro K, Kaji Y, Miller JW, D'Amore PA, Adamis AP: VEGF164 mediated inflammation is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization. J Exp Med. The Rockefeller University Press, 198 (3): 483-89. 10.1084\/jem.20022027. August 4, 2003, [http:\/\/www.jem.org\/cgi\/doi\/10.1084\/jem.20022027]","DOI":"10.1084\/jem.20022027"},{"issue":"2","key":"42_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1203\/00006450-199908000-00010","volume":"46","author":"BN Nandgaonkar","year":"1999","unstructured":"Nandgaonkar BN, Rotschild T, Yu K, Higgins RD: Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res. 1999, 46 (2): 184-8.","journal-title":"Pediatr Res"},{"issue":"1","key":"42_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1203\/00006450-199907000-00016","volume":"46","author":"T Rotschild","year":"1999","unstructured":"Rotschild T, Nandgaonkar BN, Yu K, Higgins RD: Dexamethasone reduces oxygen induce retinopathy in mouse model. Pediatr Res. 1999, 46 (1): 94-100.","journal-title":"Pediatr Res"},{"issue":"3","key":"42_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1167\/iovs.02-0392","volume":"44","author":"JL Wilkinson-Berka","year":"2003","unstructured":"Wilkinson-Berka JL, Alousis N, Kelly DJ, Gilbert RE: COX2 inhibitor and retinal angiog\u00e9nesis in a mouse model of ROP. Invest Ophthalmol Vis Sci. 2003, 44 (3): 974-9. 10.1167\/iovs.02-0392.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"42_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/sj.bjp.0704929","volume":"137","author":"S Koyama","year":"2002","unstructured":"Koyama S, Takagi H, Otani A, Oh H, Nishimura K, Honda Y: Inhibitory mechanism of vascular endothelial growth factor (VEGF) by Bucillamine. Br J Pharmacol. 2002, 137 (6): 901-9. 10.1038\/sj.bjp.0704929.","journal-title":"Br J Pharmacol"},{"key":"42_CR22","unstructured":"DRUGDEX DRUG EVALUATIONS: Ketorolac. Monograph. Access 10\/07\/00, [http:\/\/www.micromedex.com]"},{"issue":"2","key":"42_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0022-3476(96)70257-3","volume":"129","author":"CS Houck","year":"1996","unstructured":"Houck CS, Wilder RT, McDermott JS, Sethna NF, Berde CB: Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system. J Pediatr. 1996, 129 (2): 292-6.","journal-title":"J Pediatr"},{"key":"42_CR24","unstructured":"Clinical Pharmacology 2000. Gold standard multimedia. access 23\/10\/02, [http:\/\/www.cp.gsm.com]"},{"issue":"4","key":"42_CR25","first-page":"613","volume":"37","author":"PK Rabiah","year":"1996","unstructured":"Rabiah PK, Fiscella RG, Tessler HH: Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci. 1996, 37 (4): 613-8.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"42_CR26","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/S0161-6420(99)90366-4","volume":"106","author":"JM Weisz","year":"1999","unstructured":"Weisz JM, Bressler NM, Bressler SB, Schachat AP: Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology. 1999, 106 (9): 1656-9. 10.1016\/S0161-6420(99)90366-4.","journal-title":"Ophthalmology"},{"issue":"1","key":"42_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00055735-200302000-00007","volume":"14","author":"ML Nelson","year":"2003","unstructured":"Nelson ML, Martidis A: Managing cystoid macular edema after cataract surgery. Curr Opin Ophthal. 2003, 14 (1): 39-43. 10.1097\/00055735-200302000-00007.","journal-title":"Curr Opin Ophthal"},{"key":"42_CR28","first-page":"661","volume":"15","author":"RK Rajpal","year":"1999","unstructured":"Rajpal RK, Cooperman BB: Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. Ketorolac Study Group. J of Refrac Surg. 1999, 15: 661-7.","journal-title":"J of Refrac Surg"},{"issue":"5","key":"42_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1046\/j.1460-9592.2000.00534.x","volume":"10","author":"HS Bridge","year":"2000","unstructured":"Bridge HS, Montgomery CJ, Kennedy RA, Merrick PM: Analgesic efficacy of ketorolac 0.5% ophthalmic solution (accular) in paediatric strabismus surgery. Paediatr Anaesth. 2000, 10 (5): 521-6. 10.1046\/j.1460-9592.2000.00534.x.","journal-title":"Paediatr Anaesth"},{"key":"42_CR30","doi-asserted-by":"crossref","unstructured":"An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol. 1984, 102 (8): 1130-4.","DOI":"10.1001\/archopht.1984.01040030908011"},{"issue":"2","key":"42_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/archopht.1996.01100130144005","volume":"114","author":"JD Kivlin","year":"1996","unstructured":"Kivlin JD, Biglan AW, Gordon RA, Dobson V, Hardy RA, Palmer EA, Tung B, Gilbert W, Spencer R, Cheng KP, Buckley E: Early retinal vessel development and iris vessel dilatation as factors in retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Cooperative Group. Arch Ophthalmol. 1996, 114 (2): 150-4.","journal-title":"Arch Ophthalmol"},{"key":"42_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2288-3-21","volume":"3","author":"AJ Barros","year":"2003","unstructured":"Barros AJ, Hirakata VN: Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003, 3: 21-10.1186\/1471-2288-3-21.","journal-title":"BMC Med Res Methodol"},{"key":"42_CR33","unstructured":"Wright KW: Preventing Severe ROP. Research to Prevent Blindness. access: April 2003, [http:\/\/www.rpbusa.org]"},{"issue":"3","key":"42_CR34","first-page":"165","volume":"95","author":"I Waisman","year":"1997","unstructured":"Waisman I, Larriestra A, S\u00e1balo S, Monjiat M: Factores de Riesgo en la Retinopat\u00eda del Prematuro. Arch argent Pediatr. 1997, 95 (3): 165-70. tab","journal-title":"Arch argent Pediatr"},{"issue":"1","key":"42_CR35","first-page":"44","volume":"2","author":"J Liarth","year":"1999","unstructured":"Liarth J, Meneses ES, Goncalves JO, Goncalves EA, Aguiar AM: Retinopat\u00eda da prematuridade estudo epidemiologico de 384 pacientes. RASPP Rev Assoc Saude Publica def Piaui. 1999, 2 (1): 44-7. tab","journal-title":"RASPP Rev Assoc Saude Publica def Piaui"},{"issue":"4","key":"42_CR36","first-page":"181","volume":"20","author":"C Large","year":"2001","unstructured":"Large C: Estadisticas 2000. Rev HMI R Sarda. 2001, 20 (4): 181-","journal-title":"Rev HMI R Sarda"},{"key":"42_CR37","unstructured":"Neufeld MD, Williams MA, Gleason CA: A Specific Elevated Cytokine Profile Is Associated with Development of Severe Retinopathy in Very Low Birth Weight Infants:. University of Washington, Seattle, WA. [http:\/\/www.abstracts-online.com\/abstracts\/PAS\/advanced_search\/results.asp]"},{"issue":"12","key":"42_CR38","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/70995","volume":"5","author":"MK Jones","year":"1999","unstructured":"Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999, 5 (12): 1418-23. 10.1038\/70995.","journal-title":"Nat Med"},{"issue":"5","key":"42_CR39","first-page":"333","volume":"75","author":"O Ruiz Moreno","year":"2000","unstructured":"Ruiz Moreno O, Andres RC, Julvez LP, Llorens VP, Marin Del Tiempo D, Novella EF, Torron C, Honrubia FM: Antiinflammatory Capacity of the Topical Ketorolac in experimental model of Inflammation Eye. Arch Soc Esp Oftalmol. 2000, 75 (5): 333-8.","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"7","key":"42_CR40","first-page":"443","volume":"75","author":"AR Cuevas","year":"2000","unstructured":"Cuevas AR, Ruiz Moreno O, Ferrer Novella E, Torron Fernandez-Blanco C, Rojo Aragones A, Pablo Julvez LE, Honrubia Lopez FM: Study of Topical Ketorolac effect in arachidonic acid metabolism in experimental anterior uveitis. Arch Soc Esp Oftalmol. 2000, 75 (7): 443-8.","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"12","key":"42_CR41","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003, 121 (12): 1684-94. 10.1001\/archopht.121.12.1684.","journal-title":"Arch Ophthalmol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-4-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2431-4-15\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-4-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-4-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:52:05Z","timestamp":1728291125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/1471-2431-4-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1186\/1471-2431-4-15","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,7]]},"assertion":[{"value":"2 February 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"15"}}